ATE194770T1 - Verwendung von inhibitoren der 3-hydroxy-3- methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie - Google Patents

Verwendung von inhibitoren der 3-hydroxy-3- methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie

Info

Publication number: ATE194770T1
Authority: AT; Austria
Prior art keywords: hydroxy; methylglutaryl; coenzyme; agent; cancer therapy
Prior art date: 1992-05-13

Application number

AT93911242T

Other languages

English (en)

Inventor

Charles Myers

Jane Trepel

Won Ki Kang

Luke Whitesell

Len Neckers

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-13

Filing date

1993-05-12

Publication date

2000-08-15

1993-05-12 Application filed by Us Health filed Critical Us Health

2000-08-15 Application granted granted Critical

2000-08-15 Publication of ATE194770T1 publication Critical patent/ATE194770T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

AT93911242T 1992-05-13 1993-05-12 Verwendung von inhibitoren der 3-hydroxy-3- methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie ATE194770T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88222392A	1992-05-13	1992-05-13
PCT/US1993/004454 WO1993023034A1 (en)	1992-05-13	1993-05-12	Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy

Publications (1)

Publication Number	Publication Date
ATE194770T1 true ATE194770T1 (de)	2000-08-15

Family

ID=25380156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93911242T ATE194770T1 (de)	1992-05-13	1993-05-12	Verwendung von inhibitoren der 3-hydroxy-3- methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie

Country Status (12)

Country	Link
US (1)	US6040334A (de)
EP (1)	EP0642341B1 (de)
JP (1)	JPH08503451A (de)
AT (1)	ATE194770T1 (de)
AU (1)	AU683839B2 (de)
CA (1)	CA2135312C (de)
DE (1)	DE69329062T2 (de)
DK (1)	DK0642341T3 (de)
ES (1)	ES2151508T3 (de)
GR (1)	GR3034641T3 (de)
PT (1)	PT642341E (de)
WO (1)	WO1993023034A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1609469A3 (de) *	1996-12-13	2009-07-29	ZymoGenetics, Inc.	Zusammenstellungen und Methoden zur Stimulierung des Knochenwachstums
US6376476B1 (en) *	1996-12-13	2002-04-23	Zymogenetics Corporation	Isoprenoid pathway inhibitors for stimulating bone growth
EP0944312B9 (de) *	1996-12-13	2006-07-05	ZymoGenetics, Inc.	Zusammensetzungen und verfahren zum stimulieren von knochenwachstum
CA2283333A1 (en) *	1997-03-04	1998-09-11	Charles E. Elson	Method of suppressing tumor growth with combinations of isoprenoids and statins
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
US6841362B1 (en)	2000-02-29	2005-01-11	The Trustees Of Columbia University In The City Of New York	Melanoma differentiation associated gene-7 promoter and uses thereof
US7229822B1 (en)	2000-02-29	2007-06-12	Univ Columbia	Melanoma differentation associated gene-5 and vectors and cells containing same
US6376537B1 (en) *	2000-03-28	2002-04-23	Assa Weinberg	Cancer treatment
DE10057648A1 (de) *	2000-11-21	2002-06-06	Univ Jw Goethe Frankfurt Main	Verwendung von Inhibitoren von 3-Hydroxyl-3-methylglutaryl-Coenzym-A-Reduktase
BR0116302A (pt)	2000-12-19	2004-01-13	Pfizer Prod Inc	Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
US6740757B2 (en)	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US7041309B2 (en) *	2002-06-13	2006-05-09	Neuropro Technologies, Inc.	Spinal fusion using an HMG-CoA reductase inhibitor
WO2004024073A2 (en) *	2002-09-11	2004-03-25	The Board Of Trustees Of The University Of Arkansas	Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin
ES2339524B1 (es) *	2008-08-28	2011-03-22	Proyecto De Biomedicina Cima, S.L.	Nuevo biomarcador como diana terapeutica en cancer de pulmon.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS56115717A (en) *	1980-02-19	1981-09-11	Akira Endo	Preventive and remedy for prostatomegaly
US5595734A (en) *	1988-04-06	1997-01-21	Alfacell Corporation	Compositions comprising ONCONASE (tm) and lovastatin
US5130333A (en) *	1990-10-19	1992-07-14	E. R. Squibb & Sons, Inc.	Method for treating type II diabetes employing a cholesterol lowering drug

1993
- 1993-05-12 CA CA002135312A patent/CA2135312C/en not_active Expired - Lifetime
- 1993-05-12 AU AU42443/93A patent/AU683839B2/en not_active Expired
- 1993-05-12 ES ES93911242T patent/ES2151508T3/es not_active Expired - Lifetime
- 1993-05-12 JP JP6500936A patent/JPH08503451A/ja active Pending
- 1993-05-12 DE DE69329062T patent/DE69329062T2/de not_active Expired - Lifetime
- 1993-05-12 PT PT93911242T patent/PT642341E/pt unknown
- 1993-05-12 DK DK93911242T patent/DK0642341T3/da active
- 1993-05-12 AT AT93911242T patent/ATE194770T1/de active
- 1993-05-12 EP EP93911242A patent/EP0642341B1/de not_active Expired - Lifetime
- 1993-05-12 WO PCT/US1993/004454 patent/WO1993023034A1/en active IP Right Grant
1994
- 1994-10-20 US US08/330,865 patent/US6040334A/en not_active Expired - Lifetime
2000
- 2000-10-18 GR GR20000402330T patent/GR3034641T3/el unknown

Also Published As

Publication number	Publication date
CA2135312C (en)	2006-09-26
US6040334A (en)	2000-03-21
WO1993023034A1 (en)	1993-11-25
AU683839B2 (en)	1997-11-27
GR3034641T3 (en)	2001-01-31
DK0642341T3 (da)	2000-12-18
PT642341E (pt)	2001-01-31
JPH08503451A (ja)	1996-04-16
EP0642341B1 (de)	2000-07-19
EP0642341A1 (de)	1995-03-15
ES2151508T3 (es)	2001-01-01
DE69329062D1 (de)	2000-08-24
CA2135312A1 (en)	1993-11-25
AU4244393A (en)	1993-12-13
DE69329062T2 (de)	2001-03-29

Similar Documents

Publication	Publication Date	Title
ATE194770T1 (de)	2000-08-15	Verwendung von inhibitoren der 3-hydroxy-3- methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie
EP0981607A4 (de)	2004-09-01	Modifizierte arginindeaminase
DE69831222D1 (de)	2005-09-22	Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
HK1022301A1 (en)	2000-08-04	Conjugates of cisdocosahexaenoic acid and paclitaxel
UA66793C2 (uk)	2004-06-15	Лептин як стримувач швидкого збільшення пухлини клітини
ATE258437T1 (de)	2004-02-15	Chinolone und deren therapeutische verwendung
ATE399007T1 (de)	2008-07-15	Raf kinase hemmer
IL222002B (en)	2018-02-28	A preparation of taxane for the treatment of cancer, restenosis and retinopathy
ATE196844T1 (de)	2000-10-15	Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
IL124593A0 (en)	1998-12-06	Substituted aryl or heteroarylamides having retinoid-like biological activity
ID26328A (id)	2000-12-14	Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
AU7546694A (en)	1995-03-22	Monoclonal antibody that induces apoptosis
GR880100332A (el)	1989-02-23	ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ
DE69717647T2 (de)	2003-09-25	3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
DE60007120D1 (de)	2004-01-22	Isophosphoramide-senfgasanalogen und deren verwendung
NO996206L (no)	2000-02-15	Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
DE60026350D1 (de)	2006-04-27	Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel
TR199701613T1 (xx)	1998-04-21	Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
UA25582C2 (uk)	2001-07-16	Засіб для лікування гематоцитопенічних реакцій теплокровних організмів
ZA883620B (en)	1989-01-25	Phosphorus-containing hmg-coa reductase inhibitors,new intermediates and methods
SI0986387T1 (en)	2003-10-31	FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
AU5488798A (en)	1998-07-03	Synthesis of bis trialkylsilylamide and resulting composition
UA30893A (uk)	2000-12-15	Розвантажна решітка барабанного млина

Legal Events

Date	Code	Title	Description
2001-02-15	UEP	Publication of translation of european patent specification